MRI as a marker for disease heterogeneity in multiple sclerosis

Area of Science:

• Neurology
• Radiology
• Biomedical Engineering

Background:

• Multiple sclerosis (MS) is increasingly recognized as a heterogeneous disease, challenging the traditional view of it being solely inflammatory.
• Pathologic studies indicate distinct disease processes among individual MS patients, necessitating in vivo methods to understand this heterogeneity.
• Dissecting MS pathophysiology is crucial for developing targeted therapeutics and optimizing patient-specific treatment plans.

Purpose of the Study:

• To develop a stratification algorithm for MS patients using MRI metrics of inflammation and axonal damage.
• To evaluate if these identified MS subgroups maintain distinct characteristics over time.
• To enhance the prediction of clinical outcomes through a comprehensive assessment of disease activity and tissue loss.

Main Methods:

• Utilized mathematical modeling to identify three key MRI measures correlating with clinical outcomes in 71 untreated MS patients.
• Applied cross-sectional analysis to select discriminatory MRI parameters.
• Validated the stratification algorithm's generalizability using an independent longitudinal cohort of 71 MS patients.

Main Results:

• Successfully stratified MS patients into four clinically meaningful subgroups based on MRI measures of inflammation and tissue loss.
• Demonstrated the persistence of intergroup differences in MRI measures over an 8-year period in the longitudinal cohort.
• Confirmed that inflammatory activity and tissue destruction in MS can operate independently.

Conclusions:

• The inflammatory and destructive components of multiple sclerosis are partially independent processes.
• Sequential evaluation of both inflammation and tissue loss using MRI can improve the prediction of individual patient outcomes.
• This stratification approach offers a pathway for personalized medicine in multiple sclerosis management.